[{"id":"fc067e79-e4cd-4f7a-bac9-88ab15d27fb7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05191004","created_at":"2022-01-13T13:56:18.452Z","updated_at":"2024-07-02T16:35:43.452Z","phase":"Phase 1/2","brief_title":"Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC","source_id_and_acronym":"NCT05191004","lead_sponsor":"Nuvation Bio Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • inixaciclib (NUV-422)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2023-07-11"}]